The purpose of this randomized, parallel-group, single-blinded, single center, Phase II study is to collect data to compare the comfort and patient satisfaction of a hip injection delivered via the Navigator compared to a standard needle injection. In addition, delivery preparation will be compared between a Navigator injection and a standard hip injection. The data collected from this pilot study will serve as the basis to design a larger multi-center study.

Inclusion Criteria:

• Males and females, ≥18 years of age, of any race or ethnicity;
• Capable of completing self-administered questionnaires;
• Patients with suspected intra-articular hip pain who have failed conservative care (conservative care defined as a standard regimen of home or outpatient physical therapy, activity modification, trial of at least one NSAID) for at least 3 months;
• Candidate for a hip injection;
• Have been informed of the nature of the study, agreeing to its requirements, and have signed the informed consent approved by the Institutional Review Board/Ethics Committee.
• Subjects are able to understand and speak English

Exclusion Criteria:

• History of intra-articular injection within the last 3 months prior to the injection procedure;
• Complex regional pain syndrome;
• History of prior hip surgery;
• History of substance abuse;
• Known history of hypersensitivity to local anesthetics of the amide type;
• Contraindicated for Celestone (betamethasone sodium phosphate);
• Contraindicated for Lidocaine Hydrochloride;
• Is a prisoner or ward of the state;
• Are unable to meet the treatment and follow up protocol requirements.